Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ECOG-ACRIN / EA3231

Trial Overview

Official Title

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Study Purpose

To determine if cabozantinib or the combination of dabrafenib and trametinib works better to prolong the time until the tumor grows or spreads after initial treatment stops working.

Diagnosis

Radioactive Iodine-Refractory Differentiated Thyroid Cancer with BRAF V600E mutation, including papillary thyroid carcinoma and follicular thyroid carcinoma

Eligibility

Prior I-131 treatment, prior lenvatinib or sorafenib, no prior cabozantinib

Intervention

Daily oral Dabrafenib + Trametinib Vs Cabozantinib 

For more information, click the link below:

https://clinicaltrials.gov/study/NCT06475989?term=EA3231&rank=1

 

 

 

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
EA3231